Positive: Tempus AI has seen significant YTD growth, with revenue projections raised and major partnerships.

From Nasdaq: 2025-05-15 15:00:00

Tempus AI (TEM) has seen a 91.8% YTD rally, outperforming the Medical Info Systems industry and healthcare sector. Q1 2025 results show a 75.4% revenue increase and narrowed losses. A $200 million deal with AstraZeneca and Pathos boosts its AI-powered healthcare role. Revenue guidance raised to $1.25 billion for 2025.

President Trump’s healthcare reform may benefit Tempus AI by focusing on drug price cuts. Despite recent gains, TEM still trades below its 52-week high. Analysts offer a short-term price target reflecting a decline. TEM stock is slightly overvalued compared to peers. Current shareholders should hold, while new investors should wait for a better entry point.

Tempus AI presents long-term potential with genomics growth and major partnerships. The company’s Zacks Rank is a Hold due to premium valuation and competition. Positive EBITDA and EPS are yet to be delivered. Trump’s healthcare order could provide additional impetus. Current shareholders advised to hold, new investors cautious.

Five stocks predicted to double in 2024, including potential home runs under the radar. Zacks Investment Research offers free stock analysis reports on companies like AstraZeneca, iRhythm Technologies, SOPHiA GENETICS, and Tempus AI. Stay updated with the latest recommendations. Original article published on Zacks Investment Research.



Read more at Nasdaq: After 92% YTD Surge, Is Tempus AI a Buy on Trump’s Executive Order?